By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AstraZeneca Canada Inc. 

1004 Middlegate Road

Mississauga  Ontario  L4Y 1M4  Canada
Phone: 905-277-7111 Fax: 905-270-3248


Company News
AstraZeneca Canada (AZN) Release: Pan-Canadian Oncology Drug Review Recommendation Supports The Use Of Tagrisso (Osimertinib) As The Standard Of Care For T790M Mutated Non-Small Cell Lung Cancer 5/8/2017 7:32:22 AM
AstraZeneca Canada (AZN) Release: Tagrisso (Osimertinib) Demonstrates Superiority Over Chemotherapy In EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer 12/9/2016 7:16:30 AM
AstraZeneca Canada (AZN) Release: Lynparza (Olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit For Women With Ovarian Cancer 11/1/2016 6:35:34 AM
AstraZeneca Canada (AZN) Release: Canada Denies Public Access To Potentially Life-Prolonging Ovarian Cancer Treatment LYNPARZA (Olaparib) 10/5/2016 9:07:59 AM
AstraZeneca Canada (AZN) Release: TAGRISSO (Osimertinib) Approved Health Canada As Treatment For Patients With Locally Advanced Or Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer 7/11/2016 6:14:47 AM
AstraZeneca Canada (AZN) Release: Health Canada Approves LYNPARZA For The Treatment Of Ovarian Cancer In Patients With BRCA-Mutations 5/3/2016 6:19:13 AM
AstraZeneca Canada (AZN) Release: DUAKLIR GENUAIR Now Available In Canada For The Treatment Of Chronic Obstructive Pulmonary Disease 10/29/2015 10:28:35 AM
AstraZeneca Canada (AZN) Launches New FluMistĀ® Quadrivalent Flu Vaccine For This Flu Season 10/26/2015 9:41:25 AM
AstraZeneca Canada (AZN) Release: PEGASUS-TIMI 54 Study Shows That Long-Term Treatment With BRILINTA Reduced Thrombotic Cardiovascular Events In Patients With A History Of Heart Attack 3/16/2015 6:56:06 AM
AstraZeneca Canada Inc. (AZN) Release: Lose The Sugar - A New Approach In The Fight Against Type 2 Diabetes 12/17/2014 9:57:56 AM